

## Lumify<sup>™</sup> (brimonidine) – New over-the-counter drug approval

- On December 22, 2017, <u>Bausch and Lomb announced</u> the <u>FDA approval</u> of <u>Lumify (brimonidine)</u>
  0.025% ophthalmic solution, to relieve redness of the eye due to minor eye irritations.
- Lumify is the first over-the-counter (OTC) eye drop developed with low-dose brimonidine.
- Brimonidine is also available as ophthalmic prescription medications in higher doses as follows:

   0.15% solution, 0.2% solution, Alphagan® P 0.1% and 0.15% solution, 0.2% suspension in combination with brinzolamide 1% (Simbrinza®), and 0.2% solution in combination with timolol 0.5% (Combigan®).
  - These prescription strength brimonidine products are indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
- Warnings of Lumify include for external use only; do not use if solution changes color or becomes cloudy; and stop use and consult a doctor if you experience eye pain, changes in vision, continued redness or irritation of the eye, condition worsens or persists for more than 3 days.
- The recommended dosage of Lumify in adults and children ≥ 5 years is one drop into the affected eye(s) every 6 -8 hours.
  - Lumify should not be used more than four times daily.
  - Contact lenses should be removed before instilling Lumify. Lenses may be re-inserted 10 minutes after instilling Lumify.
  - If other ophthalmic products are being used, wait 5 minutes between using each product.
- Bausch and Lomb plans to launch Lumify in the second guarter of 2018.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.